Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert J Ossenkoppele

Showing results (151-160 of 193) with videos related to

Pageof 20
Sort By:
Haematologica|October 2, 2025
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncologyAnna J T Smit, Niek G Van der Maas, Bronno Van der Holt, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Blood|July 19, 2013
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPARichard F Schlenk, Erdogan Taskesen, Yvette van Norden, et al.
Blood|May 28, 2009
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderJean-Luc Harousseau, Giovanni Martinelli, Wieslaw W Jedrzejczak, et al.
ESMO Open|January 21, 2020
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignanciesBarbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
Oncotarget|October 27, 2015
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTORSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Blood Advances|January 13, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Salim Abdullah Al Hinai, et al.
Blood Advances|February 24, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Al Hinai, et al.
Blood|January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
Pageof 20

Showing results (151-160 of 193) with videos related to

Sort By:
Pageof 20
Haematologica|October 2, 2025
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncologyAnna J T Smit, Niek G Van der Maas, Bronno Van der Holt, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Blood|July 19, 2013
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPARichard F Schlenk, Erdogan Taskesen, Yvette van Norden, et al.
Blood|May 28, 2009
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderJean-Luc Harousseau, Giovanni Martinelli, Wieslaw W Jedrzejczak, et al.
ESMO Open|January 21, 2020
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignanciesBarbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
Oncotarget|October 27, 2015
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTORSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Blood Advances|January 13, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Salim Abdullah Al Hinai, et al.
Blood Advances|February 24, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Al Hinai, et al.
Blood|January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
Pageof 20